ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

23,912Medicare Part D Prescriptions Filled, Including Refills

Rank: 41 out of 3001

$1.62M Total Retail Price of All Prescriptions

Rank: 30 out of 3001

702 Patients Receiving at Least One Drug in Part D
53%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Ohio
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 702 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

14% of this provider’s 702 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 12,883 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Ohio
LISINOPRIL 797 461 1 2
FUROSEMIDE 774 392 2 6
AMLODIPINE BESYLATE 703 401 3 5
METOPROLOL TARTRATE 553 336 4 8
WARFARIN SODIUM 508 289 5 12
OMEPRAZOLE 500 283 6 4
SIMVASTATIN 462 246 7 1
HYDROCHLOROTHIAZIDE 452 177 8 10
LEVOTHYROXINE SODIUM 450 263 9 3
GABAPENTIN 413 192 10 14
HYDROCODONE-ACETAMINOPHEN 411 232 S3 11 7
POTASSIUM CHLORIDE 407 201 12 15
ATORVASTATIN CALCIUM 319 178 13 11
METFORMIN HCL 310 183 14 9
PRAVASTATIN SODIUM 285 161 15 13
LYRICA 276 173 16 87
CARVEDILOL 249 143 17 25
TRAMADOL HCL 241 116 18 17
IPRATROPIUM-ALBUTEROL 240 150 19 119
QUETIAPINE FUMARATE 238 128 20 66
TRAZODONE HCL 234 94 21 37
POLYETHYLENE GLYCOL 3350 230 191 22 55
SERTRALINE HCL 224 123 23 20
CITALOPRAM HBR 223 151 24 16
NAMENDA 220 181 25 40
OXYCODONE-ACETAMINOPHEN 201 70 S2 26 32
FAMOTIDINE 192 76 27 68
CYMBALTA 189 97 28 53
LANTUS SOLOSTAR 184 115 29 80
ZOLPIDEM TARTRATE 181 75 30 24
MIRTAZAPINE 179 121 31 44
TAMSULOSIN HCL 178 147 32 29
DONEPEZIL HCL 178 166 32 27
LANTUS 178 82 32 47
CLONIDINE HCL 164 99 35 64
JANUVIA 162 50 36 54
SPIRIVA 155 64 37 57
OXYBUTYNIN CHLORIDE ER 153 108 38 79
PREDNISONE 151 98 39 39
KLOR-CON M20 145 87 40 52
HYDRALAZINE HCL 142 115 41 104
PROMETHAZINE HCL 142 60 R 41 93
LEVETIRACETAM 140 50 43 112
NEXIUM 139 51 44 23
SODIUM CHLORIDE 139 55 44 199
BACLOFEN 137 17 46 125
NOVOLOG FLEXPEN 130 51 47 169
IBUPROFEN 128 45 48 74
METOPROLOL SUCCINATE 124 89 49 19
SPIRONOLACTONE 124 36 49 75
PROAIR HFA 123 32 51 30
EXELON 120 119 52 108
ALENDRONATE SODIUM 115 71 53 26
OXYCODONE HCL 114 26 S2 54 72
NOVOLOG 103 49 55 94
ADVAIR DISKUS 103 50 55 58
CLOPIDOGREL 102 56 57 28
ESCITALOPRAM OXALATE 102 48 57 82
PEN NEEDLE 102 55 57 128
ALBUTEROL SULFATE 100 33 60 99
ABILIFY 99 57 61 144
METOCLOPRAMIDE HCL 99 32 61 139
DIGOXIN 95 75 63 65
LOSARTAN POTASSIUM 95 54 63 21
DIVALPROEX SODIUM 92 64 65 70
GLIMEPIRIDE 89 34 66 31
NYSTATIN 89 43 66 149
MELOXICAM 89 53 66 34
FLUTICASONE PROPIONATE 88 33 69 42
VENLAFAXINE HCL ER 88 57 69 103
RISPERIDONE 87 64 71 63
ATENOLOL 85 48 72 18
ROPINIROLE HCL 85 34 72 88
SINGULAIR 84 40 74 95
CYCLOBENZAPRINE HCL 84 35 R 74 73
LISINOPRIL-HYDROCHLOROTHIAZIDE 82 62 76 22
METFORMIN HCL ER 81 20 77 51
ISOSORBIDE MONONITRATE ER 81 58 77 45
CIPROFLOXACIN HCL 79 55 79 56
NAPROXEN 78 38 80 84
PLAVIX 77 48 81 46
LOSARTAN-HYDROCHLOROTHIAZIDE 75 21 82 49
HEPARIN SODIUM 73 49 83 420
HUMALOG 73 48 83 207
PANTOPRAZOLE SODIUM 72 26 85 43
HALOPERIDOL 72 42 85 147
SULFAMETHOXAZOLE-TRIMETHOPRIM 72 47 85 77
LIPITOR 70 24 88 100
CRESTOR 70 37 88 33
VENLAFAXINE HCL 69 41 90 171
MORPHINE SULFATE ER 69 27 S2 90 150
DIOVAN 68 56 92 50
FENTANYL 66 33 S2 93 76
LEVOFLOXACIN 66 39 93 115
LABETALOL HCL 65 34 95 189
CARBIDOPA-LEVODOPA 65 55 95 97
IMIPENEM-CILASTATIN SODIUM 64 22 10 97 449
HYDROXYZINE PAMOATE 63 0 R 98 218
KLOR-CON M10 63 28 98 138
FINASTERIDE 63 54 98 92
SEROQUEL 63 39 98 146
HYDROMORPHONE HCL 61 25 S2 102 276
GLIPIZIDE 59 33 103 67
LIDODERM 58 50 104 122
FLUOXETINE HCL 56 30 105 61
CILOSTAZOL 55 50 106 224
CHLORHEXIDINE GLUCONATE 54 11 107 239
RANITIDINE HCL 54 29 107 41
IPRATROPIUM BROMIDE 54 28 107 183
TRAVATAN Z 53 53 110 230
FLUCONAZOLE 52 20 111 194
PHENYTOIN SODIUM EXTENDED 52 21 111 126
NOVOLIN R 52 22 111 174
MONTELUKAST SODIUM 51 21 114 175
DOXYCYCLINE HYCLATE 50 32 115 105
PREMARIN 50 17 R 115 214
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 10, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.